• Products
  • Cas lib
  • Buy offers
  • Encyclopedia
  • Msds lib
  • Synthesis
  • Reach Info
  • Suppliers

Top Quality Nemorubicin powder for anticancer research only

CAS: 108852-90-0
FOB Price:10 USD/Gram
Minimum Order Quantity:10/Gram
Supply Ability:1000 Kilogram/Year
Payment Terms:T/T,Western Union,MoneyGram,
Updatetime:Sep 18 2017
Company Profile
Contact:celia zhang
Address: Unit1 4Building, Su haobei Distict, Wucang District, Wuhan city, Hubei Province
Quick Details
Classification: Pharmaceutical
Cas NO.: 108852-90-0
Molecular Formula: C32H37 N O13
Melting Point:
Boiling Point: 852.2°Cat760mmHg
Water Solubility:
Refractive index:1.68
Flash Point: 469.2°C
Purity: 98
usage: For Research only
Brand Name: Demeikai
Aliase: Nemorubicin
Purity: 98
Brand: Demeikai
Target:: anticancer
MF:: C32H37NO13
MW:: 643.6351
Packaging & Delivery
Packaging Detail: foil bag
Delivery Detail: send by Fedex,DHL,TNT
Detailed Description



Nemorubicin Basic Info.




Nemorubicin Nemorubicin(Methoxymorpholinyl doxorubicin; MMDX; PNU 152243) is a 3'-deamino-3'[2-(S)-methoxy-4-morpholinyl]derivative of doxorubicin, Nemorubici has the anticancer activity on human hepatocellular carcinoma with an IC50 of 80 nM.

IC50 value: 80 nM [1]

Target: anticancer

in vitro: Methoxymorpholinyl doxorubicin (PNU 152243) is a morpholinyl analog possessing a methoxymorpholinyl group at the 3' position of the sugar moiety, which, compared with doxorubicin, appears to be less cardiotoxic and more cytotoxic against multidrug-resistant tumor cells.


Nemorubicin is a 3′-deamino-3′[2-(S)-methoxy-4-morpholinyl]derivative of doxorubicin. This derivative has been synthesized in the early 1990s by the Farmitalia CarloErba Research Center in Italy. The idea was to develop doxorubicin analogues able to circumvent the emergenceof chemoresistance, in particular the multi-drug resistance. The drug was reported to be active in vitroagainst both murine and human tumor cells resistant to doxorubicin. Similar results were obtained whenthe drug was administered in vivo to mice bearing multi-drug resistant tumors. The compound retained thesame activity also in alkylating agents and topoisomerase II resistant tumors and showed an increased potencyrelative to the parent drug doxorubicin. It is metabolized via P450 CYP3A enzyme to an extremely cytotoxicderivative. Both nemorubicin and its metabolite have a mechanism of action different from that ofdoxorubicin, with a key role played by the nucleotide excision repair system. The drug is activelytested in clinics as a single agent or in combination with cisplatin.


Related Products:

MMAE                      474645-27-7            98%

MMAD                      203849-91-6            98%

DM1                       139504-50-0            98%

Maytansinol               57103-68-1             98%

Maytansine                35846-53-8             95%

Valrubicin                56124-62-0             98%

Idarubicin hydrochloride  57852-57-0             98%

Nemorubicin               108852-90-0            98%

PNU-159682                202350-68-3            95%

Calicheamicin γ1         108212-75-5            95%

VCMMAE                    646502-53-6            95%

Company Information
Name:Wuhan Deme chem Biotechnology Co., Ltd √ Verified
Category:Corporation/Limited Liability Company
Trade Category: Trading Company√ Verified
Registered Time: 2016 √ Verified
Registered Capital: US$101 Thousand - US$500 Thousand
Legal Representative: xianghong xu√ Verified
Employees: 11 - 50 People
Address: Unit1 4Building, Su haobei Distict, Wucang District, Wuhan city, Hubei Province
Product/Service: Steroid, Active ingredient and Pharmaceutical .

Wuhan Deme chem Biotechnology Co., Ltd is a new and high-tech enterprise. The main business is research and development, production, sales for Steroid, Active ingredient and Pharmaceutical .